SARC037: A Phase I Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients

  • End date
    Jun 30, 2023
  • participants needed
  • sponsor
    Sarcoma Alliance for Research through Collaboration
Updated on 12 May 2021
measurable disease
refractory ewing sarcoma


This study evaluates the trabectedin and irinotecan in the treatment of Ewings sarcoma, with a EWS-FLI1 mutation. Patients will also receive an infusion of 18F-FLT in combination with a Positron Emission Tomography (PET) scan to help evaluate the effect of treatment.


Trabectedin and Irinotecan may inhibit the activity of this Ewing sarcoma mutation. Trabectedin may suppress the proliferation of the gene involved in DNA damage response. It blocks EWS-FLI1 by inactivating the fusion protein and silences the target genes.

Irinotecan also suppresses the genes regulating the tumor cells, generating DNA damage. Together, these drugs work in combination to suppress the gene regulating the tumor cells. This combination may suppress the activity of the tumor regulating genes, disrupting the activity of the genes. The infusion of 18F-FLT in combination with a Positron Emission Tomography (PET) scan will demonstrate whether the target cells have been suppressed.

Condition Ewing's sarcoma
Treatment Irinotecan, tumor biopsy, Trabectedin 1 MG [Yondelis], 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging
Clinical Study IdentifierNCT04067115
SponsorSarcoma Alliance for Research through Collaboration
Last Modified on12 May 2021


Yes No Not Sure

Inclusion Criteria

diagnosis of relapsed and refractory Ewing sarcoma with EWS-FLI1 fusion type for which there is no known therapy proving to prolong survival
measurable disease
ECOG Performance Status of 0-2 or Lansky of 50
adequate organ function
written, voluntary consent
willing to undergo tumor biopsy
negative hepatitis infection

Exclusion Criteria

prior therapy with trabectedin or lurbinectedin
known history of hypersensitivity to irinotecan or topotecan or their excipients
known brain metastases
known bleeding diathesis
pregnant or breastfeeding
currently receiving other investigational drugs or anticancer agents
clinically significant unrelated illness or uncontrolled infection
unable to comply with the safety monitoring requirements
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note